Broadly Neutralizing Antibodies (bNAbs) Archives

GSK-Vir therapy has neutralizing activity against Omicron sub-variant, data shows

Antibodies, Broadly Neutralizing Antibodies (bNAbs), Clinical Data, Clinical Trials, Columbia University, Covid-19 Data, COVID-19 Studies, GlaxoSmithKline, Monoclonal Antibodies, Omicron BA.2, R&D, Researchers, Sotrovimab, Vir Biotechnology

An antibody-based COVID-19 therapy developed by GSK and Vir Biotechnology retains neutralizing activity against the emerging BA.2 form of the Omicron coronavirus variant, according to data from a laboratory study cited by Vir on February 10.

February 10, 2022/by Reuters Health

Moderna’s Covid-19 vaccine shows promise against Delta variant

Broadly Neutralizing Antibodies (bNAbs), Moderna, mRNA-1273/Moderna COVID-19 Vaccine (Moderna)

Moderna Inc.’s Covid-19 vaccine produced neutralizing antibodies against emerging variants, including the Delta variant first identified in India, in a lab study.

June 29, 2021/by Andrew Humphreys

DNA Vaccine Generates Robust Responses Against Covid-19 Variants

Broadly Neutralizing Antibodies (bNAbs), Business, Clinical Trials, COVID-19 Variant B.1.1.7, Covid-19 Variants, DNA Vaccines, Interim Data, Novel Coronavirus, R&D, SARS-CoV-2 virus, Shares, T-Cells

Shares of Inovio climbed in trading after the company announced its DNA vaccine candidate for Covid-19 induced a robust T-cell response against multiple variants of the SARS-CoV-2 virus.

April 15, 2021/by Andrew Humphreys

Could Immunotherapy Replace Antiretrovirals in HIV Treatment?

Antibodies, Antiretroviral Drugs, Broadly Neutralizing Antibodies (bNAbs), FDA, HIV, Immunotherapies, Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), R&D, Researchers, Studies

An experimental HIV immunotherapy treatment is showing significant promise in clinical testing. A study shows the two-drug combination is capable of suppressing HIV for months at a time.

September 27, 2018/by BioSpace